COMMUNIQUÉS West-GlobeNewswire

CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
03/06/2025
Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology Lehi, June 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 3rd, 2025 – CancerVax, Inc., the developer of [...]
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
03/06/2025
Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the [...]
Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 €
03/06/2025
Communiqué de presse Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 € Dijon, France le 3 juin 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), [...]
Addex Convenes Annual General Meeting 2025
03/06/2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
03/06/2025
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first- [...]
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03/06/2025
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseases Under regulatory review in the US, the EU, and China in immune [...]
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose
03/06/2025
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose Quatrième désignation de médicament orphelin pour le rilzabrutinib dans les maladies rares En cours d’ [...]
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl [...]
Extendicare Acquires Nine Long-Term Care Homes from Revera
03/06/2025
MARKHAM, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“ Extendicare ”) (TSX: EXE.TO) announced today that, effective June 1, 2025, it has completed the previously announced transaction with Revera Inc. [...]
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
03/06/2025
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that [...]
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
03/06/2025
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that [...]
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
03/06/2025
Tokyo, Japan and Cambridge, UK, 3 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase [...]
Saus Trades’ Latest eBook Helps Traders Tackle the Psychological Barriers to Consistent Profitability
03/06/2025
The Trader’s Mind bridges the gap between strategy and success, offering tools like trading journals, breathing techniques, and mindset frameworks. Designed for daily use, it’s been embraced by over 20,000 traders, [...]
Canadian Health Tech Cuts Hospital Emergency Department Triage Time by up to 60%
03/06/2025
Ontario-based digital health company EmergConnect reports up to 60% reductions in emergency room triage time at hospitals using its platform. Several major Ontario hospitals now use the system Photo Courtesy of [...]
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
03/06/2025
VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“ Eupraxia ” or the “ Company ”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
03/06/2025
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1 -m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of [...]
Evils of Sham Peer Review Exposed in the Journal of American Physicians and Surgeons
02/06/2025
TUSCON, Ariz., June 02, 2025 (GLOBE NEWSWIRE) -- Unlike good-faith peer review intended to ensure good patient care, the intent of sham peer review is to inflict maximum harm on the physician victim, in pursuit of power [...]
Quest PharmaTech Provides Corporate Update
02/06/2025
EDMONTON, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for [...]

Pages